News
CanVirex in Pharma Tech Outlook – Cancer vaccination to activate anti-tumor immune response
February 17, 2021
By Stacey Smith for Pharma Tech Outlook “Cancer is a journey, but you walk the road alone. There are many places to stop along the
Two sides of the same coin: Measles-vectored drugs for cancer immunotherapy and vaccines
December 12, 2020
The CanVirex platform deploys the oncolytic properties of recombinant measles vectors for innovative cancer treatments. In addition it has now provided a novel COVID-19 vaccine
Behind CanVirex: From idea to realization
August 4, 2020
CanVirex stands for ‘fighting cancer with viruses’. Using viruses to treat cancer is an ancient idea, however only in recent decades technologies have been developed to investigate and modify these ’cancer-killing’, or ‘oncolytic’ viruses.